Safety results of a phase III randomized trial of adjuvant treatment with 5-fluorouracil and folinic acid with or without irinotecan, in Dukes B2 and C colon cancer

被引：0
|
作者：
Papakostas, P. [1 ]
Kalofonos, H. P. [1 ]
Pentheroudakis, G. [1 ]
Timotheadou, E. [1 ]
Papadimitriou, C. [1 ]
Tsavdaridis, D. [1 ]
Economopoulos, T. [1 ]
Galani, E. [1 ]
Bafaloukos, D. [1 ]
Aravantinos, G. [1 ]
机构：
[1] Hellen Cooperat Oncol Grp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4053
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
    Schmoll, Hans-Joachim
    Tabernero, Josep
    Maroun, Jean
    de Braud, Filippo
    Price, Timothy
    Van Cutsem, Eric
    Hill, Mark
    Hoersch, Silke
    Rittweger, Karen
    Haller, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3733 - +
  • [22] Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment:: results of a multicenter randomized trial
    Focan, C
    Bury, J
    Beauduin, M
    Herman, ML
    Vindevoghel, A
    Brohée, D
    Lecomte, M
    ANTI-CANCER DRUGS, 2000, 11 (07) : 549 - 554
  • [23] A RANDOMIZED TRIAL OF ORAL 5-FLUOROURACIL VERSUS PLACEBO AS ADJUVANT THERAPY IN COLORECTAL-CANCER DUKES-B AND DUKES-C - RESULTS AFTER 5 YEARS OBSERVATION TIME
    HAFSTROM, L
    RUDENSTAM, CM
    DOMELLOF, L
    BRITISH JOURNAL OF SURGERY, 1985, 72 (02) : 138 - 141
  • [24] Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
    Oettle, H
    Riess, H
    CANCER, 2002, 95 (04) : 912 - 922
  • [25] Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Michael Gubanski
    Anders Johnsson
    Eva Fernebro
    Lianna Kadar
    Ingegerd Karlberg
    Petra Flygare
    Åke Berglund
    Bengt Glimelius
    Pehr A. Lind
    Gastric Cancer, 2010, 13 : 155 - 161
  • [26] Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Gubanski, Michael
    Johnsson, Anders
    Fernebro, Eva
    Kadar, Lianna
    Karlberg, Ingegerd
    Flygare, Petra
    Berglund, Ake
    Glimelius, Bengt
    Lind, Pehr A.
    GASTRIC CANCER, 2010, 13 (03) : 155 - 161
  • [27] Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer
    Recchia, F
    Nuzzo, A
    Lalli, A
    Lombardo, M
    DiLullo, L
    Fabiani, F
    Fanini, R
    Venturoni, L
    Torchio, P
    Peretti, G
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (03): : 301 - 304
  • [28] Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer - A multicenter phase III trial
    Vaillant, JC
    Nordlinger, B
    Deuffic, S
    Arnaud, JP
    Pelissier, E
    Favre, JP
    Jaeck, D
    Fourtanier, G
    Grandjean, JP
    Marre, P
    Letoublon, C
    ANNALS OF SURGERY, 2000, 231 (04) : 449 - 456
  • [29] Folinic acid (FA) and 5-fluorouracil (FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer (ACC): Preliminary results of a randomized phase II trial
    Maiello, E
    Giuliani, F
    Gebbia, V
    Cigolari, S
    Fortunato, S
    Paoletti, G
    Borsellino, N
    Lopez, M
    Gebbia, N
    Colucci, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S71 - S71
  • [30] Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
    Bajetta, E.
    Floriani, I.
    Di Bartolomeo, M.
    Labianca, R.
    Falcone, A.
    Di Costanzo, F.
    Comella, G.
    Amadori, D.
    Pinto, C.
    Carlomagno, C.
    Nitti, D.
    Daniele, B.
    Mini, E.
    Poli, D.
    Santoro, A.
    Mosconi, S.
    Casaretti, R.
    Boni, C.
    Pinotti, G.
    Bidoli, P.
    Landi, L.
    Rosati, G.
    Ravaioli, A.
    Cantore, M.
    Di Fabio, F.
    Aitini, E.
    Marchet, A.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1373 - 1378
12345